WO2014005107A3 - Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture - Google Patents

Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture Download PDF

Info

Publication number
WO2014005107A3
WO2014005107A3 PCT/US2013/048736 US2013048736W WO2014005107A3 WO 2014005107 A3 WO2014005107 A3 WO 2014005107A3 US 2013048736 W US2013048736 W US 2013048736W WO 2014005107 A3 WO2014005107 A3 WO 2014005107A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
manufacture
methods
microparticle formulations
respiratory tract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/048736
Other languages
French (fr)
Other versions
WO2014005107A2 (en
Inventor
Tiejun Li
Brian THOME
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Priority to EP13810266.0A priority Critical patent/EP2877204A2/en
Publication of WO2014005107A2 publication Critical patent/WO2014005107A2/en
Publication of WO2014005107A3 publication Critical patent/WO2014005107A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Microparticle formulations are produced by contacting an aqueous solution of a protein or other active agent with an organic solvent, a counterion and a scavenging agent, and chilling the solution. The microparticles are useful for preparing stable, uniform pharmaceuticals of predetermined defined dimensions.
PCT/US2013/048736 2012-06-28 2013-06-28 Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture Ceased WO2014005107A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13810266.0A EP2877204A2 (en) 2012-06-28 2013-06-28 Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261665818P 2012-06-28 2012-06-28
US61/665,818 2012-06-28
US201361780126P 2013-03-13 2013-03-13
US61/780,126 2013-03-13

Publications (2)

Publication Number Publication Date
WO2014005107A2 WO2014005107A2 (en) 2014-01-03
WO2014005107A3 true WO2014005107A3 (en) 2014-05-01

Family

ID=49784043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/048736 Ceased WO2014005107A2 (en) 2012-06-28 2013-06-28 Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture

Country Status (3)

Country Link
US (1) US20140154308A1 (en)
EP (1) EP2877204A2 (en)
WO (1) WO2014005107A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037316A1 (en) * 2000-05-10 2002-03-28 Weers Jeffry G. Phospholipid-based powders for drug delivery
US20050112751A1 (en) * 2002-11-22 2005-05-26 Fang Fang Novel class of therapeutic protein based molecules
US20110171132A1 (en) * 2009-11-06 2011-07-14 Nexbio, Inc. Methods, Compounds, and Compositions for Treatment and Prophylaxis in the Respiratory Tract
US20120116062A1 (en) * 2006-01-24 2012-05-10 Malakhov Michael P Technology for preparation of macromolecular microspheres

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1885335A1 (en) * 2005-04-27 2008-02-13 BAXTER INTERNATIONAL INC. (a Delaware corporation) Surface-modified microparticles and methods of forming and using the same
GB0812742D0 (en) * 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US8389021B2 (en) * 2009-02-03 2013-03-05 Microbion Corporation Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037316A1 (en) * 2000-05-10 2002-03-28 Weers Jeffry G. Phospholipid-based powders for drug delivery
US20050112751A1 (en) * 2002-11-22 2005-05-26 Fang Fang Novel class of therapeutic protein based molecules
US20120116062A1 (en) * 2006-01-24 2012-05-10 Malakhov Michael P Technology for preparation of macromolecular microspheres
US20110171132A1 (en) * 2009-11-06 2011-07-14 Nexbio, Inc. Methods, Compounds, and Compositions for Treatment and Prophylaxis in the Respiratory Tract

Also Published As

Publication number Publication date
WO2014005107A2 (en) 2014-01-03
US20140154308A1 (en) 2014-06-05
EP2877204A2 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
HK1211468A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
MD20140072A2 (en) New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
EP2769976B8 (en) Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof
HUE042360T2 (en) Anti-parasitic preparations containing the active ingredient isoxazoline, their preparation and use
PH12014502778B1 (en) Antibody formulation
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
AR093377A1 (en) ANTI-NOTCH ANTIBODIES AND ANTIBODY-FARMACO CONJUGATES
HK1207292A1 (en) Methods and compositions for preparing a silk microsphere
BR112014024833A8 (en) VETERINARY SOFT CHEWABLE PHARMACEUTICAL PRODUCT, PROCESS FOR MANUFACTURING A PRODUCT, USE OF PAMOIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USE OF A SOFT CHEWABLE VETERINARY PHARMACEUTICAL COMPOSITION, AND, SOFT CHEWABLE VETERINARY PHARMACEUTICAL COMPOSITION.
CL2013001282A1 (en) Dimethyl amide succinate salt of 7-cyclopentyl-2- (5-piperazin-1-yl-pyridin-2-yl-amino) -7h-pyrrolo- [2,3-d] -pyrimidin-6-carboxylic acid; pharmaceutical composition that includes it and processes for its preparation.
EP2657231A4 (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
AU2013373885B2 (en) Oxazolidone compound, preparing method and application thereof
PH12016500043A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation
PH12016500814B1 (en) Heteroaryl butanoic acid derivatives
EP4282272A3 (en) Method of delivering an agriculturally active ingredient
WO2014005103A3 (en) Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture
HK1212978A1 (en) Novel derivatives of sinapinic acid
WO2014020133A3 (en) Process and device
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
WO2014005107A3 (en) Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture
WO2014184659A3 (en) Bubble encapsulation via silicilic acid complexation
ZA201508860B (en) Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EP2998302A4 (en) Novel acid dianhydride, method for preparing same, and polyimide prepared therefrom
IN2015DN02660A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13810266

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2013810266

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013810266

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13810266

Country of ref document: EP

Kind code of ref document: A2